{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T11:07:55.980157+00:00","company":{"ticker":"DERM","cik":1867066,"company_name":"Journey Medical Corp"},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"debt_financing","fact_key":"02a2da8247330fc9cdcde5da6ccb74add2e3935e","cik":1867066,"ticker":"DERM","company_name":"Journey Medical Corp","filed_at":"2025-09-26T23:59:59+00:00","payload":{"counterparty":"SWK Funding LLC","effective_date":"2025-09-25","event":"amendment","instrument_type":"term_loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"June 27, 2028","principal_text":"$25.0 million"},"claim":"Journey Medical Corp amended term loan of $25.0 million with SWK Funding LLC maturing June 27, 2028.","evidence_excerpt":"October 21, 2024 and the Third Amendment, the “Amended\nCredit Agreement”). The Amended Credit Agreement provides for a term\nloan facility in the original principal amount of $25.0 million. As of the date of this report, the Company has drawn the full $25.0 million,\nwhich is treated under the Amended Credit Agreement as a single loan (the “Term Loan”). The Third","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-093891","anchor_url":"https://secwatch.observer/filing/0001104659-25-093891#claim-02a2da8247330fc9cdcde5da6ccb74add2e3935e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925093891/0001104659-25-093891-index.htm"},{"fact_type":"governance_change","fact_key":"a56a3ea9ff4ddbab30846140eff67382b75a6098","cik":1867066,"ticker":"DERM","company_name":"Journey Medical Corp","filed_at":"2025-06-26T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-24","item_codes_triggered":["5.03"],"summary_text":"Fourth Amended and Restated Certificate of Incorporation filed to provide for officer exculpation"},"claim":"Journey Medical Corp: Fourth Amended and Restated Certificate of Incorporation filed to provide for officer exculpation (effective 2025-06-24).","evidence_excerpt":"effective upon filing, to provide for, among other things, officer exculpation","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-063032","anchor_url":"https://secwatch.observer/filing/0001104659-25-063032#claim-a56a3ea9ff4ddbab30846140eff67382b75a6098","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925063032/0001104659-25-063032-index.htm"},{"fact_type":"executive_change","fact_key":"08f3ecd754","cik":1867066,"ticker":"DERM","company_name":"Journey Medical Corp","filed_at":"2025-04-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-04-01","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Ramsey Alloush was appointed as Chief Operating Officer at Journey Medical Corp.","evidence_excerpt":"On April 1, 2025, Ramsey Alloush, the General Counsel of Journey Medical Corporation (the “ Company ”), was appointed as the Company’s Chief Operating Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-031463","anchor_url":"https://secwatch.observer/filing/0001104659-25-031463#claim-08f3ecd754","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925031463/0001104659-25-031463-index.htm"},{"fact_type":"executive_change","fact_key":"23fc75c2e0","cik":1867066,"ticker":"DERM","company_name":"Journey Medical Corp","filed_at":"2024-07-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-09","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael C. Pearce was appointed as Director at Journey Medical Corp.","evidence_excerpt":"appointed Michael C. Pearce, age 62, to serve on the Board","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-24-079596","anchor_url":"https://secwatch.observer/filing/0001104659-24-079596#claim-23fc75c2e0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924079596/0001104659-24-079596-index.htm"},{"fact_type":"earnings_release","fact_key":"210ca7991aac1997fb6600b060d3adc1cef62a2d","cik":1867066,"ticker":"DERM","company_name":"Journey Medical Corp","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":"$(0.53) per share basic and diluted","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $10.4 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":"Total net product revenues were $13.0 million"},"claim":"Journey Medical Corp reported first quarter ended March 31, 2024 results: revenue Total net product revenues were $13.0 million, net income Net loss was $10.4 million, EPS $(0.53) per share basic and diluted.","evidence_excerpt":"New Drug Application\nfor DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues\nfor the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of\n2023 Company\nto hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-060513","anchor_url":"https://secwatch.observer/filing/0001104659-24-060513#claim-210ca7991aac1997fb6600b060d3adc1cef62a2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924060513/0001104659-24-060513-index.htm"},{"fact_type":"executive_change","fact_key":"af94387750","cik":1867066,"ticker":"DERM","company_name":"Journey Medical Corp","filed_at":"2024-05-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-04-26","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Joseph Benesch was appointed as Chief Financial Officer at Journey Medical Corp.","evidence_excerpt":"On April 26, 2024, the Board of Directors (the “ Board ”) of Journey Medical Corporation (the “ Company ”) appointed Joseph Benesch, age 57, as the Company’s permanent Chief Financial Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-24-055725","anchor_url":"https://secwatch.observer/filing/0001104659-24-055725#claim-af94387750","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924055725/0001104659-24-055725-index.htm"},{"fact_type":"earnings_release","fact_key":"9bfbefc8f041bb0fbcdfd2eacd66fad0232f804b","cik":1867066,"ticker":"DERM","company_name":"Journey Medical Corp","filed_at":"2024-03-21T23:59:59+00:00","payload":{"eps_text":"$(0.21) per share basic and diluted","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(3.9) million","period_text":"the full year ended December 31, 2023","report_date":"2024-03-21","result_type":"reported_results","revenue_text":"$79.2 million"},"claim":"Journey Medical Corp reported the full year ended December 31, 2023 results: revenue $79.2 million, net income $(3.9) million, EPS $(0.21) per share basic and diluted.","evidence_excerpt":"EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Full-Year\n2023 Financial Results and Recent Corporate Highlights Company generated total revenues\nof $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in\noperating cost savings in 2023, ahead of initial","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-037318","anchor_url":"https://secwatch.observer/filing/0001104659-24-037318#claim-9bfbefc8f041bb0fbcdfd2eacd66fad0232f804b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924037318/0001104659-24-037318-index.htm"}]}